June 15, 2015 (Shareholders Foundation) - An investigation on behalf of investors of bluebird bio Inc (NASDAQ:BLUE) shares over potential securities laws violations by bluebird bio and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of bluebird bio Inc (NASDAQ:BLUE) concerning whether a series of statements by bluebird bio Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

bluebird bio Inc reported that its annual Total Revenue rose from $0.34 million in 2012 to $25.42 million in 2014. Shares of bluebird bio Inc (NASDAQ:BLUE) grew from $17.69 per share in May 2014 to as high as $$197.30 per share on May 29, 2015.

On June 9, 2015, bluebird bio Inc announced the completion of the National Institutes of Health (NIH) Recombinant DNA Advisory Committees (RAC) public review of the HGB-208 pediatric study protocol for bluebird bios LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the United States for one to two years. Shares of bluebird bio Inc (NASDAQ:BLUE) declined on June 10, 2015, to $178.02 per share.